Retraction of PNAS Paper on Pancreatic Cancer Therapy by Liaki et al.
The Proceedings of the National Academy of Sciences (PNAS) has issued a formal retraction for the research article titled "A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance," authored by Liaki and colleagues. This significant academic correction appears in Volume 123, Issue 18, dated May 2026. The original study had claimed breakthrough results in treating pancreatic cancer through a novel targeted combination therapy, suggesting it could effectively regress tumors and prevent resistance mechanisms. The retraction indicates that the findings or methodologies presented in the paper no longer meet the journal's standards for publication, potentially due to data integrity issues, experimental errors, or ethical concerns, although specific reasons are not detailed in the brief notice. This event underscores the rigorous self-correction mechanism within the scientific community, particularly in high-impact medical research. The withdrawal of such a prominent study affects the ongoing discourse on pancreatic cancer treatments and highlights the importance of reproducibility and validation in clinical pre-clinical studies. Researchers and medical professionals relying on this data must now disregard the previously published conclusions.
Wire timeline
Retraction of PNAS Paper on Pancreatic Cancer Therapy by Liaki et al.
The Proceedings of the National Academy of Sciences (PNAS) has issued a formal retraction for the research article titled "A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance," authored by Liaki and colleagues. This significant academic correction appears in Volume 123, Issue 18, dated May 2026. The original study had claimed breakthrough results in treating pancreatic cancer through a novel targeted combination therapy, suggesting it could effectively regress tumors and prevent resistance mechanisms. The retraction indicates that the findings or methodologies presented in the paper no longer meet the journal's standards for publication, potentially due to data integrity issues, experimental errors, or ethical concerns, although specific reasons are not detailed in the brief notice. This event underscores the rigorous self-correction mechanism within the scientific community, particularly in high-impact medical research. The withdrawal of such a prominent study affects the ongoing discourse on pancreatic cancer treatments and highlights the importance of reproducibility and validation in clinical pre-clinical studies. Researchers and medical professionals relying on this data must now disregard the previously published conclusions.
Proceedings of the National Academy of Sciences: Proceedings of the National Academy of Sciences: Table of Contents